Diabetes patients with comorbidities had unfavorable outcomes following COVID-19: A retrospective study

doi:10.4239/wjd.v12.i10.1789

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 10

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4485)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-8) series.

Item

Count

PDF

290

WORD

159

HTML

2065

Figures (1-2)

247

Tables (1-8)

180

Sum=2941

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

412

Download

1132

Sum=1544

Oct 15, 2021 (publication date) through May 10, 2024

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Diabetes. Oct 15, 2021; 12(10): 1789-1808
Published online Oct 15, 2021. doi: 10.4239/wjd.v12.i10.1789

Table 7 Treatments and outcomes of diabetic coronavirus disease 2019 patients using metformin and matched non-metformin, acarbose and matched non-acarbose

	Metformin (n = 50)	Matched non-Metformin (n = 50)	Acarbose (n = 46)	Matched non-acarbose (n = 46)
Treatments
Antiviral therapy	49 (98.0)	42 (84.0)^a	41 (89.1)	43 (93.5)
Antibiotic therapy	45 (90.0)	37 (74.0)^a	40 (87.0)	40 (87.0)
systemic glucocorticoids	17 (34.0)	16 (32.0)	12 (26.1)	22 (47.8)^e
Intravenous immunoglobulin	15 (30.0)	11 (22.0)	11 (23.9)	22 (47.8)^e
Renal replacement therapy	0 (0.0)	1 (2.0)	0 (0.0)	0 (0.0)
Insulin	26 (52.0)	10 (20.0)^b	23 (50.0)	39 (84.8)^g
Metformin	50	0	21 (45.7)	15 (32.6)
Sulfonylurea	18 (36.0)	1 (2.0)^c	17 (37.0)	8 (17.4)^e
DPP-4 inhibitor	3 (6.0)	0 (0.0)	3 (6.5)	3 (6.5)
Acarbose	28 (56.0)	3 (6.0)^c	46 (100.0)	0 (0.0)
thiazolidinedione	6 (12.0)	0 (0.0)^a	4 (8.7)	0 (0.0)
Oxygen support
Oxygenation	32 (64.0)	21 (42.0)	30 (65.2)	30 (65.2)
Mechanical ventilation	6 (12.0)	11 (22.0)	3 (6.5)	10 (21.7)^e
Illness severity
Severe	14 (28.0)	21 (42.0)	12 (26.1)	18 (39.1)
Complications
ARDS	4 (8.0)	8 (16.0)	1 (2.2)	8 (17.4)^e
ACI	1 (2.0)	4 (8.0)	2 (4.3)	6 (13.0)
AKI	0 (0.0)	0 (0.0)	0 (0.0)	2 (4.3)
Secondary infection	8 (16.0)	5 (10.0)	0 (0.0)	2 (4.3)
Shock	1 (2.0)	0 (0.0)	1 (2.2)	10 (21.7)^e
Hypoproteinemia < 30 g/L	9 (18.0)	5 (10.0)	10 (21.7)	6 (13.0)
Coagulopathy	6 (12.0)	9 (18.0)	8 (17.4)	10 (21.7)
Length of hospital stay, d	17.60 ± 8.74	16.80 ± 10.51	18.37 ± 8.15	16.52 ± 9.96
ICU admission	6 (12.0)	6 (12.0)	3 (6.5)	8 (17.4)
Duration from admission to ICU, d	3.83 ± 2.04	2.83 ± 2.14	6.00 (3.50-6.00)	2.50 (2.00-5.00)
Prognosis
Discharged	47 (94)	41 (82)	45 (97.8)	34 (73.9)^f
Death	3 (6.0)	9 (18)	1 (2.2)	12 (26.1)

Data are expressed as n (%), mean ± SD or median (IQR). P values were calculated by t Test, Mann-Whitney U test, χ²test, Fisher’s exact test as appropriate.

Comparison of metformin users and non-users:

^aP < 0.05.

^bP < 0.01.

^cP < 0.001.

Comparison of acarbose users and non-users:

^eP < 0.05.

^fP < 0.01.

^gP < 0.001.

ACI: Acute cardiac injury; AKI: Acute kidney injury; ARDS: Acute respiratory distress syndrome.

Citation: Luo SK, Hu WH, Lu ZJ, Li C, Fan YM, Chen QJ, Chen ZS, Ye JF, Chen SY, Tong JL, Wang LL, Mei J, Lu HY. Diabetes patients with comorbidities had unfavorable outcomes following COVID-19: A retrospective study. World J Diabetes 2021; 12(10): 1789-1808
URL: https://www.wjgnet.com/1948-9358/full/v12/i10/1789.htm
DOI: https://dx.doi.org/10.4239/wjd.v12.i10.1789